MedTrace Logo

ASPREE Cancer Endpoints Study

NCT01968798 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14500

Last updated 2021-04-05

No results posted yet for this study

Summary

The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention of Events in the Elderly (ASPREE) Study, will allow for the examination of the effect of daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected specific incident and recurrent cancer and metastases. The establishment of this ACES biobank will allow for the exploration of DNA-related molecular mechanisms of aspirin's protective effect against cancer, cancer associated mortality and metastases, using blood or saliva DNA specimens, urine, and tumor tissue.

Conditions

Interventions

DRUG

Aspirin

100mg enteric-coated aspirin, taken daily

DRUG

Placebo

100mg enteric-coated placebo, taken daily

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • National Institute on Aging (NIA)

    collaborator NIH

  • Monash University

    collaborator OTHER

  • Berman Center for Outcomes and Clinical Research

    collaborator OTHER

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • Hennepin Healthcare Research Institute

    lead OTHER

Principal Investigators

  • Anne Murray, MD, MSc · Berman Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2019-01-31
Completion
2024-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01968798 on ClinicalTrials.gov